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Abstract
Kisspeptins are a group of neuropeptides with regulatory functions related to 
puberty, fertility, and reproduction. They are primarily produced by hypothalamic 
nuclei and are thought to regulate the activity of neurons that produce gonadotropin-
releasing hormone. They are also expressed by placental syncytiotrophoblasts 
in developing pregnancies and are likely involved in the processes of trophoblast 
invasion and placentation. Similarly to beta-hCG, kisspeptins are found in maternal 
plasma during the first trimester of pregnancy and increase proportionately with 
gestational age. Because of their role in implantation, there is currently interest in 
the use of kisspeptins as minimally invasive biomarkers. It is suspected that maternal 
kisspeptin levels have diagnostic potential in identifying viable early pregnancies.
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1. Introduction
Kisspeptins are a family of neuropeptides with diverse functions in humans. 
They are cleaved from a precursor peptide encoded by the KISS-1 gene, which 
was originally identified in melanoma cells as a metastasis suppressor gene [1]. 
Expression of KISS-1 has subsequently been identified in many other cell lines, 
including those of the placenta, ovaries, and testes [2]. It is now known that kiss-
peptin plays a critical role in reproduction and fertility [3]. Kisspeptin is believed to 
regulate the secretion of gonadotropin-releasing hormone (GnRH) by integrating 
central and peripheral signals [4]. During the menstrual cycle, gonadal sex steroid 
concentrations impact the secretion of GnRH from neurons located in the hypo-
thalamus. It is hypothesized that kisspeptin mediates this hypothalamic feedback 
because 1) GnRH neurons lack gonadal sex steroid receptors but some express 
kisspeptin receptors [5–7] and 2) kisspeptin neurons express sex steroid receptors 
[8, 9]. This review will focus on the role of kisspeptins throughout the menstrual 
cycle and their potential use as a biomarker of viable pregnancy.
2. Kisspeptin in the follicular phase and periovulation
Kisspeptin neurons are primarily located in the preoptic area and hypothalamic 
arcuate nucleus and function as upstream regulators of GnRH neurons [10]. In 
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both of these anatomic locations, serum estrogen and progesterone concentrations 
have been shown to regulate kisspeptin-mediated GnRH secretion [11]. During the 
early follicular phase of the menstrual cycle, estrogen exerts negative feedback on 
GnRH stimulation of luteinizing hormone (LH) secretion. As the follicular phase 
progresses, rising estrogen levels result in pulsatile secretion of GnRH, which then 
stimulates the pulsatile release of follicle-stimulating hormone (FSH) and LH [10]. 
This pulsatile secretion pattern is likely mediated by kisspeptin through regulation 
of GnRH neurons. Involvement of kisspeptin in this regulatory pathway is sus-
pected because GnRH neurons lack estrogen and progesterone receptors, and thus 
cannot directly respond to serum sex steroid concentrations [12, 13]. The absence of 
a direct biochemical connection between the gonads and hypothalamus suggests the 
presence of an intermediary signal. This “missing link” is thought to be kisspeptin 
neurons, which express estrogen receptors and secrete a ligand that can bind to 
GnRH [12].
During the early follicular phase when follicles are underdeveloped, kisspeptin 
levels are low [4, 14]. A study by Zhai et al. showed that kisspeptin levels sharply 
increase when the dominant follicle reaches 1.2 cm in diameter [14]. Kisspeptin 
levels during the periovulatory period are then high [4, 14, 15], and may have 
potential in predicting development of the dominant ovarian follicle [14]. A study 
by Dhillo et al. demonstrated that administration of exogenous kisspeptin to 
healthy women results in increased gonadotropin secretion; this response is most 
potent during the preovulatory phase [16].
A study by Meczekalski et al. demonstrated that kisspeptin and LH are co-
secreted (i.e. each kisspeptin pulse is accompanied by a pituitary LH pulse in 
response to a hypothalamic GnRH pulse) [11]. Another study demonstrated that 
blockade of the kisspeptin receptor (GPR54) resulted in blockade of pulsatile LH 
secretion [17]. There is also topographical evidence of the connection between 
GnRH and kisspeptin neurons – in several species, it has been shown that GnRH 
neuronal axons extend from the arcuate nucleus, where kisspeptin neurons are 
located, to the median eminence, where GnRH is secreted [12]. Human studies 
have not reproducibly demonstrated this neuroanatomy for all GnRH neurons, 
which may suggest that kisspeptin neuronal connections in humans are more 
complex [11, 18].
3. Kisspeptin in ovulation
At mid-cycle, estrogen secreted by the preovulatory follicle eventually triggers 
GnRH neurons to transition from pulsatile GnRH secretion to sustained secretion. 
The mechanism by which estrogen transforms from a negative to positive feedback 
signal on the hypothalamus still remains unclear. Estrogen binds to the ERα recep-
tor on kisspeptin neurons in the arcuate nucleus, inhibiting kisspeptin secretion 
and subsequent GnRH secretion [15]. In the anteroventral periventricular nucleus, 
estrogen binds kisspeptin ERα receptors and exerts positive feedback, which 
ultimately initiates the LH surge associated with ovulation.
The sustained secretion of high concentrations of GnRH (GnRH surge) occurs 
for over 24 hours and triggers the pituitary gland to secrete high levels of LH (LH 
surge) [19]. The LH surge is what ultimately triggers ovulation [7]. The LH surge 
is also the target of at-home ovulation predictor kits [14]. This cascade of hormone 
surges is thought to be primarily regulated by kisspeptin; in fact, kisspeptin is the 
most potent activator of GnRH neurons discovered to date [5]. It is suspected that 
rising estrogen levels during the follicular phase stimulate kisspeptin neurons, 
which then activate GnRH neurons to initiate the GnRH surge [7]. In contrast, 
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administration of a monoclonal antibody that blocks kisspeptin has been shown to 
prevent ovulation in rat models [20].
It is postulated that kisspeptin could be useful as a biomarker of the periovula-
tory/ovulatory phase [14]. This would be clinically useful because kisspeptin 
surges prior to LH and therefore could predict the time of ovulation before it 
happens (rather than as it happens). The target of most ovulation prediction kits is 
LH, which surges at the time of ovulation. According to Zhai et al., the probability 
of ovulation is increased when kisspeptin surges on the 11th day and LH surges on 
the 14th day [14]. In comparison, a study by Goto et al. showed that administration 
of a kisspeptin antagonist resulted in shrinkage of ovarian follicles and delayed 
ovulation [21].
4. Kisspeptin in the luteal phase and implantation
Kisspeptin is not only expressed in the central nervous system – it also performs 
peripheral functions. Expression of kisspeptin and its receptor KISS-1 has been 
demonstrated in the human ovary, fallopian tube, uterus, and placenta [22]. It is 
thought that kisspeptin primarily functions in the hypothalamus, but also interacts 
between the signaling pathways of the central and peripheral reproductive systems 
[23]. In fact, several studies have supported the idea that kisspeptin exerts direct 
effects on ovarian tissue via ovarian kisspeptin receptors [24–26].
A number of studies have demonstrated that kisspeptin is expressed at the 
maternal-fetal interface of many species, including humans [27]. In the human 
uterus, kisspeptin is expressed in the endometrial epithelial and stromal cells, but 
not in the myometrium [28]. In the early placenta, kisspeptin is initially produced 
by villous cytotrophoblast cells, then villous syncytiotrophoblast cells and the 
placental bed [29, 30]. As pregnancy progresses, placental production of kisspeptin 
declines [31, 32].
Kisspeptin expression in the endometrium is absent during the prolifera-
tive and early secretory phases but becomes abundant during the late secretory 
phase [27, 33]. This indicates a potential role of kisspeptin in the preparation 
of endometrial tissue for implantation. Kisspeptin knockout mice exhibit thin, 
weak uteri with almost no endometrial glands, suggesting kisspeptin is an 
important regulator of normal endometrial development [34]. Kisspeptin may 
also act as a mediator that facilitates implantation of the growing embryo to 
the uterine wall. It has been shown that exogenous kisspeptin administration 
strengthens adhesion of kisspeptin-expressing trophoblast cells to collagen pres-
ent in uterine tissue [34]. Immediately after implantation, kisspeptin levels are 
known to rise; this suggests involvement of kisspeptin during the decidualiza-
tion process [35]. A study by Wu et al. demonstrated a dose-dependent relation-
ship between kisspeptin expression and inhibition of cell invasion/migration in 
human decidualized endometrial cells [29]. In contrast, a kisspeptin antagonist 
called kisspeptin 234 stimulates the process of decidual invasion and migration 
[29]. Similarly, when small interfering RNAs that antagonize kisspeptin are 
introduced, stromal decidualization is impaired [35]. In a study by Calder et al., 
ablation of the KISS-1 gene and subsequent absence of kisspeptin expression 
resulted in infertile mice [36]. Even in mice that received rescue gonadotropins 
and estradiol, which restored ovulation, the mice embryos could not implant in 
the mice that lacked KISS-1. These embryos were, however, able to implant in 
wildtype mice [36].
Kisspeptin was originally identified as a suppressor of cancer metastasis; its 
function in the regulation of cellular proliferation and growth is also integral to the 
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process of placentation. The early placenta expresses high levels of kisspeptin, per-
haps to tame the invasive and migratory capability of trophoblasts [32]. Kisspeptin 
decreases the activity of collagenases, matrix metalloproteinases, and vascular 
endothelial growth factor, which are all signaling proteins involved in trophoblast 
proliferation [31, 37]. Kisspeptin also supports the adhesion of extravillous tro-
phoblasts to the endometrium, which inhibits migration [38]. This careful balance 
between invasion and the prevention of invasion is essential to the placentation 
process as well as the appropriate remodeling of the maternal uterine wall [34]. 
As the placenta develops throughout pregnancy, it exhibits a pattern of kisspeptin 
expression that follows a circadian rhythm [39]. The term placenta demonstrates 
kisspeptin surges at 0400 and 1200 daily. This rhythm correlates with circadian 
expression of other proteins involved in placental physiology, including TNFα, 
melatonin, and oxytocin [39].
5. Kisspeptin in pregnancy
Maternal kisspeptin levels rise dramatically during pregnancy, then return to 
normal within 15 days of delivery [28]. Unlike β-hCG, kisspeptin levels rise steadily 
and do not plateau [40]. It is thought that the primary source of maternal kisspeptin 
is placental tissue [27], and that maternal kisspeptin levels reflect the volume of 
viable placental tissue [41]. Kisspeptin may be useful as a biomarker of pregnancy 
due to its association with placental invasion and apoptosis [42]. It also has potential 
utility as a biomarker of miscarriage.
Spontaneous abortion (SAB) is a common experience, seen in 10–20% of 
clinically recognized pregnancies [43]. A study by Jayasena et al. showed that 
maternal plasma kisspeptin is significantly lower in women with early pregnan-
cies who later develop SAB compared to women who have a viable intrauterine 
pregnancy (IUP) [44]. Maternal kisspeptin levels also had higher diagnostic 
performance than β-hCG in detecting SAB [44]. Wu et al. demonstrated that 
women with recurrent SAB have decreased decidual kisspeptin expression 
compared to women with IUP [45]. Kavvasoglu also showed decreased maternal 
kisspeptin levels in women with SAB compared to healthy IUPs [46]. Sullivan et 
al. validated a serum kisspeptin-54 assay as well as confirmed that maternal kis-
speptin levels are positively correlated with fetal gestational age and pregnancy 
viability [40].
There is currently no established clinical test for early miscarriage; diagnosis 
relies on serial β-hCG measurements and correlation with ultrasound. This requires 
multiple maternal encounters with the healthcare system, a prolonged timeframe, 
and can involve considerable distress of the patient and partner. Jayasena et al. 
describes the current diagnostic pathway for establishing fetal viability as having 
limited clinical utility due to delay and a high degree of uncertainty [44]. Thus, 
there is interest in establishing a more accurate and streamlined diagnostic marker 
of viable IUP vs. SAB.
Kisspeptin has been shown to be massively downregulated in the case of ectopic 
pregnancy [47]. Ectopic pregnancy occurs when a fertilized ovum implants and 
develops outside the uterine cavity. Similarly to SAB, ectopic pregnancy is currently 
diagnosed by serial β-hCG measurements in correlation with ultrasound. Definitive 
diagnosis may require direct visualization via laparoscopy [48]. A study by Romero-
Ruiz et al. explored the roll of kisspeptin in individuals with ectopic pregnancy. 
They found that maternal circulating kisspeptins gradually increased during the 
first trimester of pregnancy in healthy controls. However, in those with ectopic 
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pregnancy, kisspeptin levels were suppressed. The study correlated these results to 
levels of microRNAs (miRNA) (small noncoding RNAs that can modulate gene and 
protein expression). In particular, miR-324-3p is known to inhibit kisspeptin func-
tion. Romero-Ruiz et al. found that in ectopic pregnancies, miR-324-3p was signifi-
cantly increased in placental tissue (though maternal circulating levels were low). 
This finding suggests defective export of the miRNA from its embryonic/placental 
source in ectopic pregnancy, which may further contribute to the local suppression 
of kisspeptin. The authors suggested that correlation of maternal miR-324-3p with 
kisspeptin and β-hCG levels could provide a better modality for timely diagnosis 
of ectopic pregnancy, especially considering the stability of miRNA in maternal 
serum [46].
Kisspeptin could also have diagnostic utility in identifying women at risk of 
preeclampsia. A study by Qaio showed that the placentas of term preeclamptic 
pregnancies express significantly lower kisspeptin levels compared to healthy preg-
nancies [49]. These findings were reproduced by Farina et al., which demonstrated 
lower KISS-1 expression in preeclamptic patients compared to healthy pregnant 
patients [50]. The study also suggested KISS-1 cell-free mRNA has potential to 
serve as a predictive biomarker of preeclampsia [50]. Matjila et al. investigated 
the relationship between maternal kisspeptin levels and placental kisspeptin 
expression in preeclamptic pregnancies – they found that preeclamptic placentas 
demonstrated high kisspeptin expression but low maternal kisspeptin levels [30]. It 
is speculated that elevated kisspeptin expression in diseased placentas may inhibit 
trophoblast invasion and contribute to the development of preeclampsia [30, 34]. 
Kisspeptin therefore has potential to offer predictive information about the risk of 
preeclampsia.
6. Kisspeptin in in vitro fertilization
Because of its apparent role in reproduction and fertility, there is interest in the 
use of kisspeptin as a tool to aid in assisted reproductive technology. Exogenous 
kisspeptin has been used to trigger oocyte maturation in women undergoing in 
vitro fertilization (IVF) with very low rates of ovarian hyperstimulation syndrome 
(OHSS) [41, 51]. Oocyte maturation is the process during which an oocyte transi-
tions from metaphase I to metaphase II; at this time, it is capable of becoming fertil-
ized [51]. Jayasena et al. demonstrated that a single kisspeptin bolus was capable 
of producing an LH surge that induced oocyte maturation in women undergoing 
IVF [41]. This was an important study, as it was the first to label kisspeptin as an 
effective maturation trigger. 92% of the study participants who received kisspeptin 
had at least one embryo available for transfer [41]. A study by Owens et al. then 
demonstrated that when kisspeptin is administered as an oocyte trigger during 
IVF cycles, granulosa cell gene expression is altered in such a way that increases 
FSH and LH receptor expression [52]. This altered gene expression is postulated to 
augment downstream signaling, resulting in increased sex steroid synthesis [52]. In 
fact, kisspeptin is currently considered to be the most potent stimulator of GnRH 
secretion [53, 54].
OHSS is considered a serious adverse event during IVF treatment and is typi-
cally related to the use of hCG as a trigger for oocyte maturation. This syndrome 
is characterized by extreme vascular permeability, which can result in pleural 
effusions, ascites, renal impairment, and in severe cases, death [51]. This vascular 
permeability is a downstream effect of hCG-mediated release of vascular endo-
thelial growth factor (VEGF) from the ovary [55]. Kisspeptin has been shown to 
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directly inhibit ovarian VEGF production, which significantly decreases the risk 
of OHSS when used as a trigger for ovulation induction [56]. Moreover, kis-
speptin acts to release endogenous GnRH, which triggers an LH surge dependent 
on the individual’s own GnRH reserves, and is unlikely to excessively or patho-
logically stimulate the ovaries [57].
7. Kisspeptin in puberty
In addition to its role in pregnancy and fertility, kisspeptin is also implicated in 
sexual development in humans. The target of the kisspeptin molecule is G-protein 
coupled receptor 54 (GPR54) [58]. A study by de Roux et al. demonstrated that 
humans with a defect in the GPR54 gene exhibit isolated hypogonadotrophic 
hypogonadism, suggesting that kisspeptin is an important regulator of gonadal axis 
development [59]. This finding was then reproduced by an independent study by 
Seminara et al., who evaluated a large family with idiopathic hypogonadotrophic 
hypogonadism and generated GPR54 knockout mice, which failed to undergo 
adult sexual development and had low serum gonadotropin levels [47]. In contrast, 
exogenous kisspeptin administration in prepubertal rodents and primates has 
been shown to induce precocious puberty [60]. Furthermore, Teles et al. describes 
a female with an activating mutation of GPR54 who exhibited idiopathic central 
precocious puberty [61].
Kisspeptin is thought to be imperative in all phases of sexual development, 
beginning in the embryonic phase. During the second trimester of pregnancy, 
GnRH secretion first occurs and is required for normal testicular development 
[62]. Aberrant gonadal pathways can result in male infants born with microphallus 
or cryptorchidism [63]. Kisspeptin is suspected to be crucial in the stimulation of 
GnRH secretion in both infancy and puberty [62].
8. Conclusion
Kisspeptins have a multitude of regulatory neuroendocrine functions that span 
the sexual life cycle. Though its mechanisms are not entirely characterized, there is 
strong evidence supporting its involvement in puberty and development, ovulation, 
implantation, and pregnancy. Because of their role in these reproductive processes, 
kisspeptins have potential to be useful as biomarkers in a variety of contexts, such 
as ovulation prediction and diagnosis of viable IUP. Kisspeptins may also be useful 
in the advancement of assisted reproductive technology. Continued exploration of 
kisspeptin function will help to develop and standardize practices that harness its 
diagnostic and therapeutic potential.
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